Evidence map›Paper›PMID 34993871›Full record

ArticleJournal of general internal medicine2022

Warfarin Monitoring in Safety-Net Health Systems: Analysis by Race/Ethnicity and Language Preference.

Anjana E Sharma, Elaine C Khoong, Natalie Rivadeneira, Maribel Sierra, Margaret C Fang, Neha Gupta, Rajiv Pramanik, Helen Tran, Tyler Whitezell, Valy Fontil and 2 more

Abstract read
In one paragraph

Article in Journal of general internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anjana E SharmaDepartment of Family and Community Medicine, Center for Excellence In Primary Care, University of California San Francisco, San Francisco, USA.
Elaine C KhoongCenter for Vulnerable Populations, University of California San Francisco, San Francisco, CA, USA.
Natalie RivadeneiraDivision of General Internal Medicine at Zuckerberg San Francisco General Hospital and Trauma Center, Department of Medicine, University of California San Francisco, San Francisco, USA.
Maribel SierraCenter for Vulnerable Populations, University of California San Francisco, San Francisco, CA, USA.
Margaret C FangDivision of Hospital Medicine at UCSF Health, Department of Medicine, University of California San Francisco, San Francisco, USA.
Neha GuptaAlameda Health System, Oakland, CA, USA.
Rajiv PramanikContra Costa Health Services, Martinez, CA, USA.
Helen TranLos Angeles County Department of Health Services, Charles R. Drew University College of Medicine, Los Angeles, CA, USA.
Tyler WhitezellKern Medical, Bakersfield, CA, USA.
Valy FontilCenter for Vulnerable Populations, University of California San Francisco, San Francisco, CA, USA.
Shin-Yu LeeSan Francisco Department of Public Health (SFDPH), San Francisco Health Network (SFHN), San Francisco, USA.
Urmimala SarkarCenter for Vulnerable Populations, University of California San Francisco, San Francisco, CA, USA. Urmimala.Sarkar@ucsf.edu.ORCID http://orcid.org/0000-0003-4213-4405

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Institutional Career Development Core SupplementKL2TR001870 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SARKAR, URMIMALA · 2016 to 2025
$19.7M
UCSF Career Development Program in Implementation Research in Heart and Lung DiseasesK12HL138046 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, CATTAMANCHI, ADITHYA · 2017 to 2021
$2.9M
Investigating Failures of Notification and Monitoring in Outpatient Care: the Safety Promotion Action Research and Knowledge (SPARK) NetworkR01HS024426 · AHRQ · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SARKAR, URMIMALA · 2015 to 2017
$1.4M
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patientsK24HL141354 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FANG, MARGARET C. · 2018 to 2022
$731k
AHRQ HHS R01 HS024426NCATS NIH HHS KL2 TR001870NCATS NIH HHS UL1 TR001872NHLBI NIH HHS K12 HL138046NHLBI NIH HHS K24 HL141354
6 · The paper itself

Abstract

backgroundRacial/ethnic disparities in anticoagulation management are well established. Differences in warfarin monitoring can contribute to these disparities and should be measured.

objectiveWe assessed for differences in international normalized ratio (INR) monitoring by race/ethnicity and language preference across safety-net care systems serving predominantly low-income, ethnically diverse populations.

designCross-sectional analysis of process and safety data shared from the Safety Promotion Action Research and Knowledge Network (SPARK-Net) initiative, a consortium of five California safety-net hospital systems.

participantsEligible patients were at least 18 years old, received warfarin for at least 56 days during the measurement period from July 2015 to June 2017, and had INR testing in an ambulatory care setting at a participating healthcare system. MAIN MEASURES: We conducted a scaled Poisson regression for adjusted rate ratio of having at least one INR checked per 56-day time period for which a patient had a warfarin prescription. Adjusting for age, sex, healthcare system, and insurance status/type, we assessed for racial/ethnic and language disparities in INR monitoring. KEY

resultsOf 8129 patients, 3615 (44%) were female; 1470 (18%), Black/African American; 3354 (41%), Hispanic/Latinx; 1210 (15%), Asian; 1643 (20%), White; and 452 (6%), other. Three thousand five hundred forty-nine (45%) were non-English preferring. We did not observe statistically significant disparities in the rate of appropriate INR monitoring by race/ethnicity or language; the primary source of variation was by healthcare network. Older age, female gender, and uninsured patients had a slightly higher rate of appropriate INR monitoring, but differences were not clinically significant.

conclusionsWe did not find a race/ethnicity nor language disparity in INR monitoring; safety-net site was the main source of variation.

Indexed as

EthnicityWarfarinAdolescentCross-Sectional StudiesFemaleHumansInternational Normalized RatioLanguageMaleWarfarinanticoagulationhealth status disparitiesquality indicatorssafety-net providersWarfarin

Identifiers

PMID34993871
PMCPMC9411299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.